Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Tarsus Pharmaceuticals reported a quarterly loss of $0.60 per share, better than the Zacks Consensus Estimate of a loss of $0.68, and an improvement from a loss of $1.31 per share a year ago, representing an earnings surprise of 11.76% [1] - The company posted revenues of $66.41 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 12.33%, and significantly up from $13.08 million in the same quarter last year [2] - Over the last four quarters, Tarsus Pharmaceuticals has surpassed consensus EPS estimates four times and topped consensus revenue estimates four times as well [2] Stock Outlook - Tarsus Pharmaceuticals shares have declined approximately 17.8% since the beginning of the year, contrasting with the S&P 500's gain of 1.7% [3] - The company's earnings outlook is currently favorable, with a Zacks Rank of 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.69 on revenues of $62.81 million, and for the current fiscal year, it is -$1.44 on revenues of $316.68 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tarsus Pharmaceuticals belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]